BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 27648841)

  • 21. Bevacizumab for non-small-cell lung cancer: A nested case control study of risk factors for hemoptysis.
    Goto K; Endo M; Kusumoto M; Yamamoto N; Ohe Y; Shimizu A; Fukuoka M
    Cancer Sci; 2016 Dec; 107(12):1837-1842. PubMed ID: 27714941
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cabozantinib for metastatic breast carcinoma: results of a phase II placebo-controlled randomized discontinuation study.
    Tolaney SM; Nechushtan H; Ron IG; Schöffski P; Awada A; Yasenchak CA; Laird AD; O'Keeffe B; Shapiro GI; Winer EP
    Breast Cancer Res Treat; 2016 Nov; 160(2):305-312. PubMed ID: 27714541
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Systematic Analysis of Tyrosine Kinase Inhibitor Response to RET Gatekeeper Mutations in Thyroid Cancer.
    Meng S; Wu H; Wang J; Qiu Q
    Mol Inform; 2016 Oct; 35(10):495-505. PubMed ID: 27712045
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Survival Outcomes in EGFR Mutation-Positive Lung Cancer Patients Treated with Gefitinib until or beyond Progression.
    Moiseyenko FV; Moiseyenko VM; Aleksakhina SN; Chubenko VA; Volkov NM; Kozyreva KS; Kramchaninov MM; Zhuravlev AS; Shelekhova KV; Ivantsov AO; Venina AR; Preobrazhenskaya EV; Mitiushkina NV; Iyevleva AG; Imyanitov EN
    Oncol Res Treat; 2016; 39(10):605-614. PubMed ID: 27710972
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of oxaliplatin, bevacizumab and oral S-1 for advanced recurrent colorectal cancer.
    Suzuki S; Shimazaki J; Morishita K; Koike N; Harada N; Hayashi T; Suzuki M
    Mol Clin Oncol; 2016 Oct; 5(4):391-394. PubMed ID: 27699032
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Efficacy of Bevacizumab in Different Line Chemotherapy for Chinese Patients with Metastatic Colorectal Cancer.
    Yin C; Ma G; Rong Y; Kong P; Yang Q; Jiang C; Liao F; Zhang B; He W; Xia L
    J Cancer; 2016; 7(13):1901-1906. PubMed ID: 27698931
    [No Abstract]   [Full Text] [Related]  

  • 27. Glioblastoma multiforme: Effect of hypoxia and hypoxia inducible factors on therapeutic approaches.
    Huang WJ; Chen WW; Zhang X
    Oncol Lett; 2016 Oct; 12(4):2283-2288. PubMed ID: 27698790
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Economic evaluation of eribulin as second-line treatment for metastatic breast cancer in South Korea.
    Tremblay G; Majethia U; Breeze JL; Kontoudis I; Park J
    Clinicoecon Outcomes Res; 2016; 8():485-493. PubMed ID: 27698565
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Goserelin plus tamoxifen compared to chemotherapy followed by tamoxifen in premenopausal patients with early stage-, lymph node-negative breast cancer of luminal A subtype.
    Alramadhan M; Ryu JM; Rayzah M; Nam SJ; Kim SW; Yu J; Lee SK; Bae SY; Park S; Paik HJ; Lee JE
    Breast; 2016 Dec; 30():111-117. PubMed ID: 27697675
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase 2 Study of Erlotinib in Combination With Linsitinib (OSI-906) or Placebo in Chemotherapy-Naive Patients With Non-Small-Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations.
    Leighl NB; Rizvi NA; de Lima LG; Arpornwirat W; Rudin CM; Chiappori AA; Ahn MJ; Chow LQ; Bazhenova L; Dechaphunkul A; Sunpaweravong P; Eaton K; Chen J; Medley S; Poondru S; Singh M; Steinberg J; Juergens RA; Gadgeel SM
    Clin Lung Cancer; 2017 Jan; 18(1):34-42.e2. PubMed ID: 27686971
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Short-term EGFR blockade enhances immune-mediated cytotoxicity of EGFR mutant lung cancer cells: rationale for combination therapies.
    Dominguez C; Tsang KY; Palena C
    Cell Death Dis; 2016 Sep; 7(9):e2380. PubMed ID: 27685624
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Axillary lymph node micrometastases decrease triple-negative early breast cancer survival.
    Houvenaeghel G; Sabatier R; Reyal F; Classe JM; Giard S; Charitansky H; Rouzier R; Faure C; Garbay JR; Daraï E; Hudry D; Gimbergues P; Villet R; Lambaudie E
    Br J Cancer; 2016 Oct; 115(9):1024-1031. PubMed ID: 27685443
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oral Bisphosphonates and Improved Survival of Breast Cancer.
    Rennert G; Pinchev M; Gronich N; Saliba W; Flugelman A; Lavi I; Goldberg H; Fried G; Steiner M; Bitterman A; Landsman K; Rennert HS
    Clin Cancer Res; 2017 Apr; 23(7):1684-1689. PubMed ID: 27683176
    [No Abstract]   [Full Text] [Related]  

  • 34. Population-Based Patterns and Factors Associated With Underuse of Palliative Systemic Therapy in Elderly Patients With Metastatic Colon Cancer.
    Chan M; Hugh-Yeun K; Gresham G; Speers CH; Kennecke HF; Cheung WY
    Clin Colorectal Cancer; 2017 Jun; 16(2):147-153. PubMed ID: 27670894
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Plasma levels of trastuzumab in gastric cancer: Case report.
    González-García J; Alonso-Alvarez B; Nazco-Casariego GJ; Batista-López N; Guttiérrez-Nicolás F
    J Oncol Pharm Pract; 2017 Dec; 23(8):635-637. PubMed ID: 27664112
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of ADAM17 in tumorigenesis and progression of breast cancer.
    Shen H; Li L; Zhou S; Yu D; Yang S; Chen X; Wang D; Zhong S; Zhao J; Tang J
    Tumour Biol; 2016 Sep; ():. PubMed ID: 27658778
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Patients with Metastatic Colorectal Cancer and Hyperbilirubinemia Treated with FOLFIRI plus Bevacizumab as First-Line Treatment.
    Huang CW; Yeh YS; Ma CJ; Tsai HL; Chen CW; Huang MY; Lu CY; Wu JY; Wang JY
    Chemotherapy; 2017; 62(1):80-84. PubMed ID: 27654129
    [TBL] [Abstract][Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.